SCYX Q1 2025 Earnings — SCYNEXIS, Inc. Revenue & Financial Results | Market Cap Arena

SCYXSCYNEXIS, Inc.

$38M

Q1 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$257,000-81.3% YoY

Gross Profit

$257,000100.0% margin

Operating Income

-$9M-3350.2% margin

Net Income

-$5M-2097.7% margin

EPS (Diluted)

$-0.11

QoQ Revenue Growth

-73.7%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$819,000

Balance Sheet

Total Assets

$68M

Total Liabilities

$17M

Stockholders' Equity

$51M

Cash & Equivalents

$7M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$257,000	$1M	-81.3%
Gross Profit	$257,000	$1M	-81.3%
Operating Income	-$9M	-$10M	+9.4%
Net Income	-$5M	$411,000	-1411.7%

Revenue Segments

License and Service

$257,000100%